Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2605
Source ID: NCT05390892
Associated Drug: Sglt2 Inhibitor
Title: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Acronym: PRECIDENTD
Status: RECRUITING
Study Results: NO
Results:
Conditions: Type2Diabetes|ASCVD
Interventions: DRUG: SGLT2 inhibitor|DRUG: GLP-1 receptor agonist
Outcome Measures: Primary: Total (first and recurrent) cardiovascular, kidney, and death events, total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, Through study completion, with an average follow up of approximately 3 years |
Sponsor/Collaborators: Sponsor: Brigham and Women's Hospital | Collaborators: Patient-Centered Outcomes Research Institute
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 6000
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
Start Date: 2022-09-26
Completion Date: 2029-03-01
Results First Posted:
Last Update Posted: 2024-05-21
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, United States|Essentia Health, Duluth, Minnesota, 55805, United States|University of Missouri-Columbia, Columbia, Missouri, 65212, United States|Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University, New York, New York, 10032, United States|Duke University Hospital, Durham, North Carolina, 27710, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
URL: https://clinicaltrials.gov/show/NCT05390892

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress